Glidiab is an oral hypoglycemic drug.
Release form and composition
Glidiab is available in the form of tablets containing:
- 80 mg of gliclazide;
- Auxiliary components: potato starch, lactose monohydrate, talc, magnesium stearate, microcrystalline cellulose, sodium carboxymethyl starch, hypromellose.
Also, the drug is available in the form of tablets with modified release of Glidiab MB, containing:
- 30 mg gliclazide;
- Additional components: hypromellose, magnesium stearate, colloidal silicon dioxide, microcrystalline cellulose.
Implemented tablets of 10 pcs. in blisters, 6 pcs. in cardboard packs.
Indications for use
According to the instructions to Glidiab, the only indication for the use of the drug is type 2 diabetes. Assign this drug in case of ineffectiveness of diet and moderate physical exertion.
The use of Glidiab, according to the instructions, is contraindicated in:
- Diabetes mellitus type one;
- Severe hepatic / renal failure;
- Diabetic ketoacidosis;
- Hyperosmolar coma;
- Diabetic precoma and coma;
- Paresis of the stomach;
- Intestinal obstruction;
- Extensive surgeries, serious injuries, burns and other conditions that require compulsory insulin therapy;
- Infectious diseases and conditions involving a violation of food absorption and the development of hypoglycemia.
In addition, the drug should not be taken:
- During pregnancy;
- Women who breastfeed;
- When hypersensitivity to gliclazide or any auxiliary component.
Careful medical supervision during the period of Glidiab and individual dose selection is required for alcohol abusers, patients with febrile syndrome and diseases of the thyroid gland.
Dosing and Administration
The specific dosage of the medication is determined by the doctor taking into account the patient's age, the clinical symptoms of the disease, and the level of glycemia (the sugar level is checked on an empty stomach and 2 hours after eating).
As a rule, the initial daily dose of Glidiab is 80 mg, the average dosage is 160 mg, the maximum permissible dose is 320 mg. The drug should be taken 30-60 minutes before a meal, twice a day.
The initial dose of Glidiab MB is 30 mg (1 tab.). With a lack of therapeutic effect once every two weeks, the dosage can be gradually increased to a maximum daily dose of 120 mg (Table 4). Modified-release tablets should be taken once a day - during breakfast.
If necessary, Glidiab MB can be used in combination with other hypoglycemic agents - insulin, alpha-glucosidase inhibitors, biguanides.
When using Glidiab, the following side effects may occur:
- On the part of the digestive system: anorexia (its severity can be reduced if you take the drug during a meal), dyspepsia (heaviness in the epigastrium, diarrhea, nausea), abnormal liver function, including cholestatic jaundice and increased activity of hepatic transaminases;
- Allergic reactions: maculopapular rash, urticaria, itching;
- On the part of the blood system: leukopenia, thrombocytopenia, anemia.
If Glidiab dosing regimen is violated and an inadequate diet is observed, hypoglycemia may develop, a pathological condition characterized by a decrease in glucose level below 3.5 mmol / l and peripheral blood below normal. This condition may be accompanied by headache, hunger and fatigue, severe weakness, increased sweating, irritability, anxiety, inattention, aggressiveness, inability to concentrate, blurred vision, slow reaction, depression, helplessness, tremor, sensory disorders, aphasia, dizziness, hypersomnia , convulsions, loss of consciousness, delirium, shallow breathing, loss of self-control, bradycardia.
An overdose of Glidiab can also lead to the development of hypoglycemia, even hypoglycemic coma. In the event that a patient who has taken an excessively large dose of the drug is conscious, he should immediately take a solution of sugar or dextrose inside. If a person is unconscious, then a 40% dextrose solution is injected into / in, glucagon - in / m. After recovery, it is imperative to give the patient food rich in easily digestible carbohydrates.
Drug treatment must complement low-calorie diet with low carbohydrate content.
During the period of use Glidiaba should regularly check the level of fasting glucose and after meals.
During the period of therapy it is strictly forbidden to starve, drink alcohol and take nonsteroidal anti-inflammatory drugs, because increases the risk of hypoglycemia. In addition, ethanol can cause disulfiram-like syndrome.
Preparations containing the same active ingredient: Gliclade, Gliclazide MV, Gliclazide-AKOS, Glyukostabil, Diabetalong, Diabeton MV, Diabefarm, Diabefarm MV, Diabinax, Diatica.
By the same pharmacological subgroup ( ". Hypoglycemic drugs for oral Sulfonylureas") apply a similar mechanism of action characterized by the following drugs: Glemaz, Amaryl, Glemauno, Glibenez retard Glibeks, glibenclamide, glimepiride, Glidanil, Glimidstada, Glyurenorm, Glyumedeks, Diamerid , Movogleklen, Maninil, Maniglid, Meglimid, Chlorpropamid.
Terms and conditions of storage
Glidiab is a prescription drug.
Tablets should be stored in a dry place, inaccessible to penetration of moisture and exposure to sunlight, at temperatures up to 25 ºС. Subject to these conditions, the shelf life of Glidiab is 4 years, and Glidiab MB is 2 years.